Targets › LPL
1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Dec 2026.
Key enzyme in triglyceride metabolism. Catalyzes the hydrolysis of triglycerides from circulating chylomicrons and very low density lipoproteins (VLDL), and thereby plays an important role in lipid clearance from the blood stream, lipid utilization and storage. (UniProt, P06858)
Open in Phaseline: the race on LPL, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| GeneCradle | GC304 self-complementary AAV5 carrying codon-optimized LPL gene driven by liver-specific promote | LPL | Phase 1 | Hypertriglyceridemia, Familial | Dec 2026 |
Hypertriglyceridemia, Familial (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.